In the DAWN study, five TBL1XR1 somatic mutations were found in nonresponders, indicating that mutations in this gene lead to alternative, BTK‐independent NF‐κB‐activation and, therefore, resistance to ibrutinib, as reported in certain MCL cell lines.45 The gene discussed is TBL1XR1; the disease is mantle cell lymphoma.